Illumina, Inc. (NASDAQ:ILMN) Position Increased by Capital World Investors

Capital World Investors increased its position in Illumina, Inc. (NASDAQ:ILMN) by 408.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 18,025,301 shares of the life sciences company’s stock after purchasing an additional 14,481,232 shares during the period. Capital World Investors owned about 0.11% of Illumina worth $2,408,721,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Bank of Stockton grew its holdings in shares of Illumina by 3.8% during the fourth quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after buying an additional 80 shares in the last quarter. Stephens Inc. AR grew its stake in Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after acquiring an additional 90 shares in the last quarter. Spire Wealth Management grew its stake in Illumina by 26.0% during the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock valued at $63,000 after acquiring an additional 97 shares in the last quarter. IFP Advisors Inc increased its holdings in shares of Illumina by 19.1% in the 4th quarter. IFP Advisors Inc now owns 617 shares of the life sciences company’s stock valued at $82,000 after purchasing an additional 99 shares during the period. Finally, Freedom Investment Management Inc. lifted its position in shares of Illumina by 3.7% in the fourth quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company’s stock worth $382,000 after purchasing an additional 101 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ILMN has been the topic of several research analyst reports. Canaccord Genuity Group lowered their price target on shares of Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a report on Tuesday, March 11th. Stephens reissued an “overweight” rating and set a $156.00 price objective on shares of Illumina in a report on Tuesday, March 11th. Morgan Stanley reduced their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a report on Tuesday, February 11th. Barclays lowered their price target on Illumina from $100.00 to $77.00 and set an “underweight” rating on the stock in a report on Thursday, April 10th. Finally, HSBC cut shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective for the company. in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $138.70.

Illumina Stock Performance

Shares of Illumina stock opened at $71.21 on Friday. The stock has a market cap of $11.27 billion, a price-to-earnings ratio of -9.27, a P/E/G ratio of 1.60 and a beta of 1.38. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The company’s fifty day moving average is $84.61 and its 200 day moving average is $120.40.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.